New Liquid Biopsy for Lung Cancer Has High Detection Rate
Delfi Diagnostics’s lung cancer screening technology, which analyzes genome-wide cell-free DNA fragmentation profiles, detected 90% of cases.
Read MorePosted by Chris Wolski | Aug 20, 2021 | Lung Cancer |
Delfi Diagnostics’s lung cancer screening technology, which analyzes genome-wide cell-free DNA fragmentation profiles, detected 90% of cases.
Read MorePosted by Chris Wolski | Jul 16, 2021 | Colorectal, Urinalysis & Toxicology |
MIT engineers have created a diagnostic nanoparticle that can identify cancer through a urine test and act as an imaging agent, pinpointing the tumor location.
Read MorePosted by Chris Wolski | Jul 9, 2021 | Cancer |
Cancer screening tests rebounded in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic.
Read MorePosted by Chris Wolski | Jul 2, 2021 | Diagnostic Technologies |
University of Michigan researchers have found evidence suggesting that preoperative testing is often unnecessary for low-risk surgeries.
Read MorePosted by Melanie Hamilton-Basich | Jun 22, 2021 | Digital Pathology |
Epredia has been appointed as a global distribution partner for Aiforia’s portfolio of preclinical and clinical pathology tools, including segment exclusivity for distribution in the United States.
Read More